Share on Facebook
Share on Twitter
Share on LinkedIn

NEW YORK (Reuters) – Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September, following a recall of much of the drug’s supply.

Chinese pharmaceutical ingredient manufacturer Zhejiang Huahai Pharmaceuticals recalled valsartan from consumers in the United States in July after finding traces of a probable carcinogen.

According to the National Average Drug Acquisition Cost (NADAC) survey for last month, prices for 160 milligram and 80 milligram tablets of the drug more than doubled last month from August rates.

Read More